China Medical GatewayLoading your healthcare gateway…

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) — Hangzhou

Hospital Profile

Zhejiang Cancer Hospital (Cancer Hospital Affiliated to the University of Chinese Academy of Sciences) was founded in October 1963 and is one of the four earliest specialized cancer hospitals established in New China. It integrates prevention, medical treatment, research, teaching, and rehabilitation. The hospital has the Banshan Campus, Shaoxing Campus (under construction), and several affiliated branch hospitals, forming a layout of one hospital with three areas. It has received the highest rating in the national performance assessment of tertiary public hospitals for five consecutive years and ranked 3rd among specialized cancer hospitals nationwide in 2023; it has been listed in the top 10 of the Fudan edition of China Hospital Oncology Specialty Comprehensive Rankings for 11 consecutive years. The hospital leads the construction of the National Cancer Regional Medical Center and was among the first to be selected for the National Difficult Disease Diagnosis and Treatment Capability Improvement Project. It is committed to becoming a 'domestic benchmark, internationally renowned, and the patient’s preferred research-oriented cancer center.'

Medical Milestones

Founded in 1963; in 2019, it was designated as the Affiliated Cancer Hospital of the University of Chinese Academy of Sciences, among others; in 2020, it co-established a campus with Shaoxing. In 2020, it ranked 3rd nationwide among oncology specialty hospitals in the first national performance evaluation of public hospitals. Zhejiang Province's cancer registry data has been 100% included in the China Cancer Registry Annual Report for 13 consecutive years. The hospital is affiliated with the Institute of Basic Medical Sciences and Cancer Research of the Chinese Academy of Sciences, and it is the location of the National Heavy Ion (Hangzhou) Clinical Treatment Research Center.

Key Capabilities & Patient Care

It has departments such as surgical oncology, medical oncology, and radiotherapy, and has established four major centers for gastric cancer, maxillofacial and head & neck, breast, and thoracic tumors. The single-disease MDT model covers common diseases, and its medical service volume ranks among the top in the country. Among the 25 key tumor surgeries monitored annually, 3 rank first in the province, 7 rank second, and 18 rank within the top 5, with the proportion of grade III–IV surgeries leading Zhejiang for seven consecutive years. The oncology department is a national clinical key specialty and has 8 national and provincial key disciplines (specialties). It undertakes the province's tumor prevention, control, and quality management work.

Advanced Technology

Equipped with high-end devices such as the Da Vinci surgical robot, heavy ion, CyberKnife, TOMO, Varian linear accelerator, etc.; the National Heavy Ion (Hangzhou) Clinical Treatment Research Center has been established. There are multiple key laboratories, and the tumor specimen bank has over 300,000 samples. • Bed capacity: Banshan Campus has 1,910 approved beds (2024-2026); Shaoxing Campus planned for 2,500 beds (to open in 2026) • Total staff: approximately over 3,000 (2026) • Inpatients: 49,300 visits (2023) • Outpatient and emergency visits: over 1.48 million (2023) • Inpatient and elective surgeries: 16,100 cases (2023, excluding outpatient surgeries) • Number of senior physicians: total number not disclosed; estimated around 450-600 (based on 3,000 staff and 15%-20% holding senior titles). Reference: In the Oncology Center, out of 85 doctors, there are 20 directors and 27 associate directors.

International Patient Services

Extensively exchanges with well-known medical schools in the United States, Japan, Germany, Russia, Singapore, and other countries in talent cultivation, scientific research, and clinical diagnosis and treatment; forms international research collaboration teams in oncology; approved as the Zhejiang Provincial International Science and Technology Cooperation Base for Precision Treatment of Thoracic Tumors.

Return to Home